Theseus Pharmaceuticals (THRX) IPO Opens 30% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Theseus Pharmaceuticals Announces Pricing of Initial Public Offering
October 6, 2021 10:21 PM EDTCAMBRIDGE, Mass., Oct. 6, 2021 /PRNewswire/ --Â Theseus Pharmaceuticals, Inc. ("Theseus"), a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced the pricing of its initial public offering of 10,000,200 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being offered by Theseus. The gross proceeds to Theseus from the offering, before deducting underwriting discounts, commissions and other offering expenses payable by Theseus, are expected to be $160 million. In addition, Theseus has granted the underwriters a... More
